Rutul R. Shah, Chief Operating Officer of Precigen, Inc., sold 50,000 shares of common stock for approximately $375,000 in two transactions executed under a pre-arranged Rule 10b5-1 trading plan.
The sales occurred on August 21 and August 25, 2026, at $7.50 per share. Precigen’s common stock closed at $7.20 on August 25, down 3.23% on the day, after trading as high as $7.55 over the prior 52 weeks.
Shah’s transactions followed the exercise of stock options and the vesting of restricted stock units. He acquired 50,000 shares via option exercises at $2.33 per share on August 21 and August 25. Additionally, 7,500 RSUs vested on August 23, representing the right to receive an equivalent number of Precigen shares. The total value of shares acquired through options and RSUs amounted to $116,500.
Tax obligations related to the RSU settlement were settled on August 23, with 3,647 shares withheld at $7.20 each, totaling approximately $26,258 in withheld value.
Precigen reported strong second-quarter results, posting earnings per share of $0.05, ahead of the expected loss of $0.01. Revenue reached $54.98 million, nearly double the forecast of $27.83 million, while net income totaled $20.1 million, marking a return to profitability driven by robust demand for PAPZIMEOS, the company’s therapy for adult recurrent respiratory papillomatosis.
